anticoagulant reversal
Contents
Match urgency to agent: warfarin → 4-factor PCC + IV vitamin K for life-threatening bleeding. Dabigatran → idarucizumab (complete reversal in minutes). Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) → andexanet alfa if available, otherwise 4-factor PCC. Heparins → protamine (full reversal for UFH, partial for LMWH). Always: resuscitate, source control, hold anticoagulant, transfuse PRN.
general principles
- Stop the anticoagulant
- Resuscitate — IV access, crossmatch, volume
- Source control — endoscopy, IR, surgery as indicated
- Reverse — agent-specific (below)
- Transfuse — platelets if <50, cryoprecipitate if fibrinogen <1.5 g/L, RBCs as needed
- Document time of last anticoagulant dose — drives reversal decisions (DOACs cleared within 24–48h in normal renal function)
Minor bleeding (epistaxis, small haematoma, haematuria without haemodynamic compromise) → hold the anticoagulant, local measures, reassess. Reserve specific reversal agents for life-threatening or critical-organ bleeding (ICH, massive GI, pericardial, retroperitoneal) and urgent surgery.
warfarin reversal
| scenario | approach |
|---|---|
| life-threatening bleeding (ICH, massive GI) | 4-factor PCC 25–50 IU/kg IV + vitamin K 10 mg IV (slow infusion over 20 min) |
| serious bleeding (non-life-threatening) | vitamin K 5–10 mg IV; consider PCC if INR >4 or ongoing |
| INR >10, no bleeding | hold warfarin + vitamin K 2.5–5 mg PO |
| INR 4.5–10, no bleeding | hold 1–2 doses; consider vitamin K 1–2 mg PO |
| urgent surgery (within 6h) | 4-factor PCC + vitamin K 10 mg IV |
- 4-factor PCC (Octaplex, Beriplex) contains factors II, VII, IX, X + protein C/S → reverses INR within 15–30 minutes
- Vitamin K takes 6–12 hours for effect but sustains reversal (PCC alone wears off in 6–8h → INR re-rises without vitamin K)
- FFP — inferior to PCC (volume overload, slower, incomplete correction); use only if PCC unavailable
IV route preferred for serious/life-threatening bleeding (onset 6–12h). Anaphylactoid reactions rare but real — infuse slowly over ≥20 minutes, have resuscitation available. SC absorption is erratic — avoid.
DOAC reversal
dabigatran → idarucizumab
- Idarucizumab (Praxbind) 5 g IV (two 2.5 g boluses ≤15 min apart)
- Humanised monoclonal antibody fragment binding dabigatran with 350× higher affinity than thrombin
- RE-VERSE AD (2017) — complete reversal of anticoagulant effect within minutes in 98% of patients
- No prothrombotic signal (does not activate coagulation cascade)
- Cleared renally — effective even if dabigatran is still being absorbed
factor xa inhibitors (apixaban, rivaroxaban, edoxaban) → andexanet alfa or PCC
Andexanet alfa (Ondexxya) — recombinant modified factor Xa decoy that sequesters Xa inhibitors.
| last DOAC dose | regimen |
|---|---|
| apixaban ≤5 mg or rivaroxaban ≤10 mg, or >18h since any dose | low dose: 400 mg bolus → 4 mg/min × 120 min |
| apixaban >5 mg or rivaroxaban >10 mg, and ≤18h since dose | high dose: 800 mg bolus → 8 mg/min × 120 min |
- ANNEXA-4 (2019) — 82% achieved excellent/good haemostasis at 12h
- Thrombotic risk ~10% within 30 days — significant; only use for truly life-threatening bleeding
- Rebound anticoagulant effect possible after infusion ends (Xa inhibitor redistributes from tissues)
- Cost: extremely expensive ($25,000–50,000 CAD per treatment)
If andexanet unavailable → 4-factor PCC 50 IU/kg
- Evidence is observational but supports PCC as a reasonable alternative
- Does not directly reverse the DOAC but provides substrate to overwhelm Xa inhibition
- Some centres use PCC first-line given cost and thrombotic risk of andexanet
heparin reversal
| agent | reversal | dose | notes |
|---|---|---|---|
| UFH | protamine | 1 mg per 100 IU heparin given in preceding 2–3h (max 50 mg) | full reversal; infuse slowly (hypotension, anaphylaxis, bradycardia) |
| LMWH | protamine | 1 mg per 1 mg enoxaparin (if <8h); 0.5 mg per 1 mg if 8–12h | ~60% reversal of anti-Xa activity; incomplete |
| fondaparinux | no specific reversal | consider rFVIIa (off-label) | long half-life (17h); PCC may help; clinical data limited |
Higher risk in patients with prior protamine exposure (e.g. NPH insulin users — protamine is a component), fish allergy (historical concern, likely overstated), or rapid IV push. Always give slowly over 10 minutes. Have adrenaline available.
when to restart anticoagulation
The hardest decision — balancing re-bleeding against thrombotic risk.
| scenario | typical restart | notes |
|---|---|---|
| GI bleeding (source controlled) | 48–72 hours | endoscopic haemostasis confirmed |
| ICH | 7–14 days (if any) | shared decision — high re-bleed risk; some never restart; consider LAA occlusion for AF |
| post-surgical bleeding | 48–72 hours | once surgical team confirms haemostasis |
| mechanical valve | as soon as safe (24–48h) | highest thrombotic risk — involve cardiac surgery |
quick reference by agent
| anticoagulant | reversal agent | onset | completeness |
|---|---|---|---|
| warfarin | 4F-PCC + vitamin K | PCC: 15–30 min; vit K: 6–12h | complete |
| DOACs (dabigatran) | idarucizumab 5 g IV | minutes | complete |
| DOACs (Xa inhibitors) | andexanet alfa; PCC if unavailable | bolus: 2–5 min | ~82% good/excellent |
| heparins (UFH) | protamine | 5–10 min | complete |
| heparins (LMWH) | protamine (partial) | 5–10 min | ~60% |
| fondaparinux | rFVIIa (off-label) | variable | incomplete |
related: DOACs · warfarin · heparins · periprocedural anticoagulation